Comparative Bioavailability Study of Metformin/Sitagliptin 850 mg/50 mg Tablets in Healthy Male and Female Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-22

Study Completion Date

2017-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of metformin/sitagliptin after a single oral dose administration under fed conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers

NCT05549583

Bioequivalence Type 2 Diabetes

COMPLETED PHASE1

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

NCT00961857

Type 2 Diabetes

COMPLETED PHASE1

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

NCT00961480

Type 2 Diabetes

COMPLETED PHASE1

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.

NCT06124547

Bioequivalence Diabetes Mellitus, Type 2

COMPLETED PHASE1

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

NCT06124560

Bioequivalence Diabetes Mellitus, Type 2

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bioequivalence Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Reference group

Thirty minutes after the start of the breakfast, a single dose of the Reference formulation was administered with approximately 240 mL of water at ambient temperature

Group Type EXPERIMENTAL

Sitagliptin/Metformin HCl 50/850 mg film-coated tablet

Intervention Type DRUG

The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/850 mg film-coated tablet

Test group

Thirty minutes after the start of the breakfast, a single dose of the Test formulation was administered with approximately 240 mL of water at ambient temperature

Group Type EXPERIMENTAL

Sitagliptin/Metformin HCl 50/850 mg film-coated tablet

Intervention Type DRUG

The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/850 mg film-coated tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sitagliptin/Metformin HCl 50/850 mg film-coated tablet

The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/850 mg film-coated tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* non- or ex-smokers
* body mass index (BMI) within 18.5 to 30.0 kg/m2, inclusively
* no clinically significant abnormality found in the 12-lead electrocardiogram (ECG) performed at study entry
* negative pregnancy test for female subjects
* healthy according to medical history, complete physical examination (including vital signs) and laboratory tests (general biochemistry, hematology and urinalysis)

Exclusion Criteria

* Females who were pregnant or were lactating
* History of significant hypersensitivity to metformin, sitagliptin or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
* Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
* History of significant gastrointestinal, liver or kidney disease that may have affected drug bioavailability
* Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
* History of or disposition to seizures, state of confusion, clinically relevant psychiatric diseases
* Presence of out-of-range cardiac interval (PR \< 110 msec, PR \> 200 msec, QRS \< 60 msec, QRS \>119 msec and QTc \> 450 msec for males and QTc \> 460 for females) on the screening ECG or other clinically significant ECG abnormalities
* Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (\> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
* Any clinically significant illness in the previous 28 days before day 1 of this study
* Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's Wort), in the previous 28 days before day 1 of this study
* Any history of tuberculosis and/or prophylaxis for tuberculosis
* Positive screening of alcohol and/or drugs of abuse
* Positive results to HIV Ag/Ab Combo, Hepatitis B surface Antigen (HBsAG (B) (hepatitis B)) or Hepatitis C Virus (HCV (C)) tests
* Females who were pregnant according to a positive pregnancy test
* Volunteers who took metformin and/or sitagliptin in the previous 28 days before day 1 of this study
* Volunteers who took an Investigational Product (in another clinical trial) in the previous 28 days before day 1 of this study
* Volunteers who had already participated in this clinical study
* Volunteers who donated 50 mL or more of blood in the previous 28 days before day 1 of this study
* Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes